[
    {
        "id": 3641,
        "drug_name": "MARGENZA (margetuximab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Metastatic breast cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-09-07",
        "link": "http:\/\/ir.macrogenics.com\/news-releases\/news-release-details\/macrogenics-announces-final-overall-survival-results-sophia",
        "note": "Final overall survival data did not demonstrate MARGENZA plus chemotherapy had a statistically significant advantage compared to trastuzumab plus chemotherapy; September 7, 2021. ",
        "company_entity_id": 197,
        "company_ticker": "MGNX",
        "company_name": "MacroGenics Inc.",
        "company_price": "17.6000",
        "company_change": 0.66,
        "company_percent_change": 3.9,
        "company_optionable": 1,
        "company_number_of_shares": 62432013,
        "price_change_sparkline": [
            [
                14.3,
                1706677200
            ],
            [
                15.27,
                1706763600
            ],
            [
                15.445,
                1706850000
            ],
            [
                16.75,
                1707109200
            ],
            [
                17.26,
                1707195600
            ],
            [
                17.43,
                1707282000
            ],
            [
                18.3,
                1707368400
            ],
            [
                17.32,
                1707454800
            ],
            [
                17.92,
                1707714000
            ],
            [
                17.35,
                1707800400
            ],
            [
                17.13,
                1707886800
            ],
            [
                17.4,
                1707973200
            ],
            [
                17.28,
                1708059600
            ],
            [
                17.17,
                1708405200
            ],
            [
                17.04,
                1708491600
            ],
            [
                17.11,
                1708578000
            ],
            [
                18.14,
                1708664400
            ],
            [
                16.81,
                1708923600
            ],
            [
                17.26,
                1709010000
            ],
            [
                17.19,
                1709096400
            ],
            [
                17.94,
                1709182800
            ],
            [
                19.06,
                1709269200
            ],
            [
                20.72,
                1709528400
            ],
            [
                20.64,
                1709614800
            ],
            [
                21.47,
                1709701200
            ],
            [
                20.51,
                1709787600
            ],
            [
                17.43,
                1709874000
            ],
            [
                16.94,
                1710129600
            ],
            [
                17.6,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3641,
        "drug_name": "MARGENZA (margetuximab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Metastatic breast cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-09-07",
        "link": "http:\/\/ir.macrogenics.com\/news-releases\/news-release-details\/macrogenics-announces-final-overall-survival-results-sophia",
        "note": "Final overall survival data did not demonstrate MARGENZA plus chemotherapy had a statistically significant advantage compared to trastuzumab plus chemotherapy; September 7, 2021. ",
        "company_entity_id": 484,
        "company_ticker": "ZLAB",
        "company_name": "Zai Lab Limited",
        "company_price": "19.5400",
        "company_change": -0.47,
        "company_percent_change": -2.35,
        "company_optionable": 1,
        "company_number_of_shares": 99208743,
        "price_change_sparkline": [
            [
                21.57,
                1706677200
            ],
            [
                22.51,
                1706763600
            ],
            [
                22.5,
                1706850000
            ],
            [
                22.12,
                1707109200
            ],
            [
                21.61,
                1707195600
            ],
            [
                19.66,
                1707282000
            ],
            [
                19.605,
                1707368400
            ],
            [
                18.68,
                1707454800
            ],
            [
                18.21,
                1707714000
            ],
            [
                17.73,
                1707800400
            ],
            [
                19.39,
                1707886800
            ],
            [
                19.89,
                1707973200
            ],
            [
                20.64,
                1708059600
            ],
            [
                19.24,
                1708405200
            ],
            [
                19.91,
                1708491600
            ],
            [
                20.08,
                1708578000
            ],
            [
                19.94,
                1708664400
            ],
            [
                20.99,
                1708923600
            ],
            [
                22.49,
                1709010000
            ],
            [
                20.8,
                1709096400
            ],
            [
                20.98,
                1709182800
            ],
            [
                21.1,
                1709269200
            ],
            [
                20.42,
                1709528400
            ],
            [
                18.91,
                1709614800
            ],
            [
                19.8,
                1709701200
            ],
            [
                19.16,
                1709787600
            ],
            [
                18.91,
                1709874000
            ],
            [
                20.01,
                1710129600
            ],
            [
                19.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5508,
        "drug_name": "BRUKINSA (zanubrutinib)",
        "clinical_trial_id": "NCT03846427",
        "has_trial_insight_page": 0,
        "indication": "Marginal Zone Lymphoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-09-15",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210915005310\/en\/U.S.-FDA-Grants-BRUKINSA%C2%AE-Zanubrutinib-Accelerated-Approval-in-Relapsed-or-Refractory-Marginal-Zone-Lymphoma",
        "note": "Approved September 15, 2021. ",
        "company_entity_id": 340,
        "company_ticker": "BGNE",
        "company_name": "BeiGene Ltd.",
        "company_price": "163.7500",
        "company_change": -0.78,
        "company_percent_change": -0.47,
        "company_optionable": 1,
        "company_number_of_shares": 104577940,
        "price_change_sparkline": [
            [
                148.23,
                1706677200
            ],
            [
                149.93,
                1706763600
            ],
            [
                144.48,
                1706850000
            ],
            [
                141.81,
                1707109200
            ],
            [
                153.58,
                1707195600
            ],
            [
                147.76,
                1707282000
            ],
            [
                142.88,
                1707368400
            ],
            [
                146.98,
                1707454800
            ],
            [
                146.57,
                1707714000
            ],
            [
                141.8,
                1707800400
            ],
            [
                145.87,
                1707886800
            ],
            [
                146.07,
                1707973200
            ],
            [
                148.23,
                1708059600
            ],
            [
                148.05,
                1708405200
            ],
            [
                150.8,
                1708491600
            ],
            [
                153.78,
                1708578000
            ],
            [
                155.1,
                1708664400
            ],
            [
                160.26,
                1708923600
            ],
            [
                179.69,
                1709010000
            ],
            [
                178.48,
                1709096400
            ],
            [
                165.65,
                1709182800
            ],
            [
                165.02,
                1709269200
            ],
            [
                167.86,
                1709528400
            ],
            [
                160.42,
                1709614800
            ],
            [
                159.52,
                1709701200
            ],
            [
                162.25,
                1709787600
            ],
            [
                158.52,
                1709874000
            ],
            [
                164.53,
                1710129600
            ],
            [
                163.75,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6615,
        "drug_name": "EXKIVITY (Mobocertinib)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Non-small cell lung cancer (NSCLC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-09-15",
        "link": "https:\/\/www.takeda.com\/newsroom\/newsreleases\/2021\/takeda-exkivity-mobocertinib-approved-by-us-fda\/",
        "note": "Approved September 15, 2021.",
        "company_entity_id": 751,
        "company_ticker": "TAK",
        "company_name": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1\/2 of a share of)",
        "company_price": "14.3700",
        "company_change": -0.19999999999999996,
        "company_percent_change": -1.37,
        "company_optionable": 1,
        "company_number_of_shares": 3137776702,
        "price_change_sparkline": [
            [
                14.6,
                1706677200
            ],
            [
                14.38,
                1706763600
            ],
            [
                14.28,
                1706850000
            ],
            [
                13.92,
                1707109200
            ],
            [
                14.16,
                1707195600
            ],
            [
                14.18,
                1707282000
            ],
            [
                14,
                1707368400
            ],
            [
                14.24,
                1707454800
            ],
            [
                14.31,
                1707714000
            ],
            [
                14.34,
                1707800400
            ],
            [
                14.54,
                1707886800
            ],
            [
                14.42,
                1707973200
            ],
            [
                14.62,
                1708059600
            ],
            [
                14.82,
                1708405200
            ],
            [
                14.74,
                1708491600
            ],
            [
                14.64,
                1708578000
            ],
            [
                14.62,
                1708664400
            ],
            [
                14.81,
                1708923600
            ],
            [
                14.84,
                1709010000
            ],
            [
                14.65,
                1709096400
            ],
            [
                14.59,
                1709182800
            ],
            [
                14.56,
                1709269200
            ],
            [
                14.48,
                1709528400
            ],
            [
                14.4,
                1709614800
            ],
            [
                14.69,
                1709701200
            ],
            [
                14.86,
                1709787600
            ],
            [
                14.77,
                1709874000
            ],
            [
                14.57,
                1710129600
            ],
            [
                14.37,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7234,
        "drug_name": "BYOOVIZ",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Biosimilar (ranibizumab)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-09-20",
        "link": "https:\/\/investors.biogen.com\/news-releases\/news-release-details\/fda-approves-samsung-bioepis-and-biogens-byooviztm-sb11",
        "note": "Approved September 20, 2021. ",
        "company_entity_id": 375,
        "company_ticker": "BIIB",
        "company_name": "Biogen Inc.",
        "company_price": "227.3600",
        "company_change": -2.71,
        "company_percent_change": -1.1800000000000002,
        "company_optionable": 1,
        "company_number_of_shares": 145360798,
        "price_change_sparkline": [
            [
                246.66,
                1706677200
            ],
            [
                247.83,
                1706763600
            ],
            [
                243.72,
                1706850000
            ],
            [
                241.84,
                1707109200
            ],
            [
                245.55,
                1707195600
            ],
            [
                240.54,
                1707282000
            ],
            [
                240.3,
                1707368400
            ],
            [
                240.98,
                1707454800
            ],
            [
                244.74,
                1707714000
            ],
            [
                226.65,
                1707800400
            ],
            [
                220.74,
                1707886800
            ],
            [
                223.35,
                1707973200
            ],
            [
                219.08,
                1708059600
            ],
            [
                219.21,
                1708405200
            ],
            [
                221.11,
                1708491600
            ],
            [
                222.48,
                1708578000
            ],
            [
                223.32,
                1708664400
            ],
            [
                223.71,
                1708923600
            ],
            [
                223.94,
                1709010000
            ],
            [
                221.74,
                1709096400
            ],
            [
                216.99,
                1709182800
            ],
            [
                220.95,
                1709269200
            ],
            [
                221.02,
                1709528400
            ],
            [
                217.23,
                1709614800
            ],
            [
                217.56,
                1709701200
            ],
            [
                219.36,
                1709787600
            ],
            [
                223.24,
                1709874000
            ],
            [
                230.07,
                1710129600
            ],
            [
                227.36,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7484,
        "drug_name": "TIVDAK (tisotumab vedotin)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Cervical Cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-09-20",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210920005921\/en\/",
        "note": "Approved September 20, 2021.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7484,
        "drug_name": "TIVDAK (tisotumab vedotin)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Cervical Cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-09-20",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210920005921\/en\/",
        "note": "Approved September 20, 2021.",
        "company_entity_id": 684,
        "company_ticker": "GMAB",
        "company_name": "Genmab A\/S",
        "company_price": "31.4300",
        "company_change": -0.25,
        "company_percent_change": -0.79,
        "company_optionable": 1,
        "company_number_of_shares": 660745350,
        "price_change_sparkline": [
            [
                27.61,
                1706677200
            ],
            [
                28.17,
                1706763600
            ],
            [
                27.8,
                1706850000
            ],
            [
                27.57,
                1707109200
            ],
            [
                28.15,
                1707195600
            ],
            [
                27.97,
                1707282000
            ],
            [
                27.79,
                1707368400
            ],
            [
                27.84,
                1707454800
            ],
            [
                27.49,
                1707714000
            ],
            [
                26.43,
                1707800400
            ],
            [
                27.59,
                1707886800
            ],
            [
                28.23,
                1707973200
            ],
            [
                28.71,
                1708059600
            ],
            [
                28.95,
                1708405200
            ],
            [
                28.95,
                1708491600
            ],
            [
                29.11,
                1708578000
            ],
            [
                29.16,
                1708664400
            ],
            [
                29.4,
                1708923600
            ],
            [
                29.05,
                1709010000
            ],
            [
                27.67,
                1709096400
            ],
            [
                27.77,
                1709182800
            ],
            [
                29.29,
                1709269200
            ],
            [
                28.51,
                1709528400
            ],
            [
                28.75,
                1709614800
            ],
            [
                28.86,
                1709701200
            ],
            [
                29.41,
                1709787600
            ],
            [
                30.3,
                1709874000
            ],
            [
                31.68,
                1710129600
            ],
            [
                31.43,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4702,
        "drug_name": "Opzelura (Ruxolitinib)",
        "clinical_trial_id": "NCT03745638",
        "has_trial_insight_page": 0,
        "indication": "Atopic dermatitis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-09-21",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210921006072\/en\/",
        "note": "Approved September 21, 2021. ",
        "company_entity_id": 167,
        "company_ticker": "INCY",
        "company_name": "Incyte Corporation",
        "company_price": "59.3300",
        "company_change": -1.46,
        "company_percent_change": -2.4,
        "company_optionable": 1,
        "company_number_of_shares": 224526128,
        "price_change_sparkline": [
            [
                58.77,
                1706677200
            ],
            [
                59.16,
                1706763600
            ],
            [
                58.35,
                1706850000
            ],
            [
                58.06,
                1707109200
            ],
            [
                59.63,
                1707195600
            ],
            [
                57.34,
                1707282000
            ],
            [
                57.36,
                1707368400
            ],
            [
                57.66,
                1707454800
            ],
            [
                57.84,
                1707714000
            ],
            [
                59.34,
                1707800400
            ],
            [
                57.89,
                1707886800
            ],
            [
                58.97,
                1707973200
            ],
            [
                57.96,
                1708059600
            ],
            [
                58.82,
                1708405200
            ],
            [
                60.33,
                1708491600
            ],
            [
                60.91,
                1708578000
            ],
            [
                60.59,
                1708664400
            ],
            [
                60.53,
                1708923600
            ],
            [
                61,
                1709010000
            ],
            [
                59.98,
                1709096400
            ],
            [
                58.36,
                1709182800
            ],
            [
                59.05,
                1709269200
            ],
            [
                59.72,
                1709528400
            ],
            [
                58.9,
                1709614800
            ],
            [
                59.26,
                1709701200
            ],
            [
                59.03,
                1709787600
            ],
            [
                60.02,
                1709874000
            ],
            [
                60.79,
                1710129600
            ],
            [
                59.33,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2722,
        "drug_name": "JAKAFI (Ruxolitinib)",
        "clinical_trial_id": "NCT03112603",
        "has_trial_insight_page": 0,
        "indication": "Steroid-refractory chronic GVHD (Graft versus host disease)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-09-22",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210922005863\/en\/",
        "note": "Approved September 22, 2021.",
        "company_entity_id": 167,
        "company_ticker": "INCY",
        "company_name": "Incyte Corporation",
        "company_price": "59.3300",
        "company_change": -1.46,
        "company_percent_change": -2.4,
        "company_optionable": 1,
        "company_number_of_shares": 224526128,
        "price_change_sparkline": [
            [
                58.77,
                1706677200
            ],
            [
                59.16,
                1706763600
            ],
            [
                58.35,
                1706850000
            ],
            [
                58.06,
                1707109200
            ],
            [
                59.63,
                1707195600
            ],
            [
                57.34,
                1707282000
            ],
            [
                57.36,
                1707368400
            ],
            [
                57.66,
                1707454800
            ],
            [
                57.84,
                1707714000
            ],
            [
                59.34,
                1707800400
            ],
            [
                57.89,
                1707886800
            ],
            [
                58.97,
                1707973200
            ],
            [
                57.96,
                1708059600
            ],
            [
                58.82,
                1708405200
            ],
            [
                60.33,
                1708491600
            ],
            [
                60.91,
                1708578000
            ],
            [
                60.59,
                1708664400
            ],
            [
                60.53,
                1708923600
            ],
            [
                61,
                1709010000
            ],
            [
                59.98,
                1709096400
            ],
            [
                58.36,
                1709182800
            ],
            [
                59.05,
                1709269200
            ],
            [
                59.72,
                1709528400
            ],
            [
                58.9,
                1709614800
            ],
            [
                59.26,
                1709701200
            ],
            [
                59.03,
                1709787600
            ],
            [
                60.02,
                1709874000
            ],
            [
                60.79,
                1710129600
            ],
            [
                59.33,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2989,
        "drug_name": "REPATHA (evolocumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Cardiovascular disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-09-24",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-approves-repatha-evolocumab-in-pediatric-patients-age-10-and-older-with-heterozygous-familial-hypercholesterolemia-301385035.html",
        "note": "Approved for pediatric patients 10 years and older September 24, 2021.",
        "company_entity_id": 372,
        "company_ticker": "AMGN",
        "company_name": "Amgen Inc.",
        "company_price": "276.5400",
        "company_change": 1.18,
        "company_percent_change": 0.43,
        "company_optionable": 1,
        "company_number_of_shares": 535918901,
        "price_change_sparkline": [
            [
                311.832823699025,
                1706677200
            ],
            [
                322.053272003295,
                1706763600
            ],
            [
                320.693853151174,
                1706850000
            ],
            [
                319.483275779212,
                1707109200
            ],
            [
                313.62884422628,
                1707195600
            ],
            [
                293.584858231498,
                1707282000
            ],
            [
                292.572736166415,
                1707368400
            ],
            [
                288.871544693121,
                1707454800
            ],
            [
                292.155980021969,
                1707714000
            ],
            [
                288.236487711108,
                1707800400
            ],
            [
                287.829654332006,
                1707886800
            ],
            [
                289.07,
                1707973200
            ],
            [
                283.7,
                1708059600
            ],
            [
                283.51,
                1708405200
            ],
            [
                283.46,
                1708491600
            ],
            [
                285.18,
                1708578000
            ],
            [
                289.18,
                1708664400
            ],
            [
                286.37,
                1708923600
            ],
            [
                278.49,
                1709010000
            ],
            [
                277.46,
                1709096400
            ],
            [
                273.83,
                1709182800
            ],
            [
                280.33,
                1709269200
            ],
            [
                279.39,
                1709528400
            ],
            [
                276.65,
                1709614800
            ],
            [
                276.59,
                1709701200
            ],
            [
                272.86,
                1709787600
            ],
            [
                273.75,
                1709874000
            ],
            [
                275.36,
                1710129600
            ],
            [
                276.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8295,
        "drug_name": "ERBITUX (cetuximab injection) + BRAFTOVI (encorafenib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Metastatic colorectal cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-09-28",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-expands-lillys-erbitux-cetuximab-label-with-combination-of-braftovi-encorafenib-for-the-treatment-of-braf-v600e-mutation-positive-metastatic-colorectal-cancer-crc-after-prior-therapy-301387268.html",
        "note": "Approved September 28, 2021.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8295,
        "drug_name": "ERBITUX (cetuximab injection) + BRAFTOVI (encorafenib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Metastatic colorectal cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-09-28",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-expands-lillys-erbitux-cetuximab-label-with-combination-of-braftovi-encorafenib-for-the-treatment-of-braf-v600e-mutation-positive-metastatic-colorectal-cancer-crc-after-prior-therapy-301387268.html",
        "note": "Approved September 28, 2021.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3005,
        "drug_name": "QULIPTA (Atogepant)",
        "clinical_trial_id": "NCT03777059",
        "has_trial_insight_page": 0,
        "indication": "Chronic migraine",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-09-28",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-approves-qulipta-atogepant-the-first-and-only-oral-cgrp-receptor-antagonist-specifically-developed-for-the-preventive-treatment-of-migraine-301387297.html",
        "note": "Approved September 28, 2021. ",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5932,
        "drug_name": "LIVMARLI (Maralixibat)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Alagille Syndrome (ALGS)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-09-29",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210929005810\/en\/",
        "note": "Approved September 29, 2021.",
        "company_entity_id": 685,
        "company_ticker": "MIRM",
        "company_name": "Mirum Pharmaceuticals Inc.",
        "company_price": "27.4800",
        "company_change": 0.54,
        "company_percent_change": 2,
        "company_optionable": 1,
        "company_number_of_shares": 46614274,
        "price_change_sparkline": [
            [
                26.46,
                1706677200
            ],
            [
                26.59,
                1706763600
            ],
            [
                26.52,
                1706850000
            ],
            [
                26.27,
                1707109200
            ],
            [
                27.21,
                1707195600
            ],
            [
                26.76,
                1707282000
            ],
            [
                27.02,
                1707368400
            ],
            [
                27.98,
                1707454800
            ],
            [
                29.93,
                1707714000
            ],
            [
                28.08,
                1707800400
            ],
            [
                28.47,
                1707886800
            ],
            [
                28.98,
                1707973200
            ],
            [
                29.28,
                1708059600
            ],
            [
                29.09,
                1708405200
            ],
            [
                28.29,
                1708491600
            ],
            [
                28.22,
                1708578000
            ],
            [
                27.81,
                1708664400
            ],
            [
                29.06,
                1708923600
            ],
            [
                29.61,
                1709010000
            ],
            [
                28.89,
                1709096400
            ],
            [
                28.71,
                1709182800
            ],
            [
                29.27,
                1709269200
            ],
            [
                28.68,
                1709528400
            ],
            [
                28,
                1709614800
            ],
            [
                28.41,
                1709701200
            ],
            [
                28.21,
                1709787600
            ],
            [
                28.15,
                1709874000
            ],
            [
                26.94,
                1710129600
            ],
            [
                27.48,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3218,
        "drug_name": "BRIUMVI - (Ublituximab)",
        "clinical_trial_id": "NCT03277261",
        "has_trial_insight_page": 0,
        "indication": "Multiple Sclerosis",
        "label": "BLA Filing",
        "value": "blaFiling",
        "simplified_stage": "phase4",
        "stageid": 12,
        "stage_name": "BLA Filing",
        "date": "2021-09-30",
        "link": "https:\/\/ir.tgtherapeutics.com\/news-releases\/news-release-details\/tg-therapeutics-submits-biologics-license-application-us-food",
        "note": "BLA submitted September 30, 2021.",
        "company_entity_id": 292,
        "company_ticker": "TGTX",
        "company_name": "TG Therapeutics Inc.",
        "company_price": "15.8400",
        "company_change": -0.53,
        "company_percent_change": -3.24,
        "company_optionable": 1,
        "company_number_of_shares": 154420772,
        "price_change_sparkline": [
            [
                16.24,
                1706677200
            ],
            [
                16.88,
                1706763600
            ],
            [
                16.46,
                1706850000
            ],
            [
                15.31,
                1707109200
            ],
            [
                15.35,
                1707195600
            ],
            [
                14.37,
                1707282000
            ],
            [
                14.64,
                1707368400
            ],
            [
                14.74,
                1707454800
            ],
            [
                15.18,
                1707714000
            ],
            [
                13.93,
                1707800400
            ],
            [
                14.19,
                1707886800
            ],
            [
                14.4,
                1707973200
            ],
            [
                13.83,
                1708059600
            ],
            [
                13.23,
                1708405200
            ],
            [
                13.02,
                1708491600
            ],
            [
                13.44,
                1708578000
            ],
            [
                13.32,
                1708664400
            ],
            [
                13.36,
                1708923600
            ],
            [
                13.91,
                1709010000
            ],
            [
                17.63,
                1709096400
            ],
            [
                17.22,
                1709182800
            ],
            [
                17.96,
                1709269200
            ],
            [
                17.87,
                1709528400
            ],
            [
                18.08,
                1709614800
            ],
            [
                18.23,
                1709701200
            ],
            [
                18,
                1709787600
            ],
            [
                16.78,
                1709874000
            ],
            [
                16.37,
                1710129600
            ],
            [
                15.84,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3322,
        "drug_name": "TECARTUS (brexucabtagene autoleucel)",
        "clinical_trial_id": "NCT02614066",
        "has_trial_insight_page": 0,
        "indication": "Adult patients with r\/r ALL - cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-10-01",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20211001005719\/en\/",
        "note": "Approved October 1, 2021.",
        "company_entity_id": 378,
        "company_ticker": "GILD",
        "company_name": "Gilead Sciences Inc.",
        "company_price": "75.0800",
        "company_change": -0.24,
        "company_percent_change": -0.31999999999999995,
        "company_optionable": 1,
        "company_number_of_shares": 1245774616,
        "price_change_sparkline": [
            [
                78.26,
                1706677200
            ],
            [
                78.16,
                1706763600
            ],
            [
                76.96,
                1706850000
            ],
            [
                76.71,
                1707109200
            ],
            [
                77.72,
                1707195600
            ],
            [
                74.42,
                1707282000
            ],
            [
                73.8,
                1707368400
            ],
            [
                73.67,
                1707454800
            ],
            [
                74.45,
                1707714000
            ],
            [
                73.53,
                1707800400
            ],
            [
                73.04,
                1707886800
            ],
            [
                73.37,
                1707973200
            ],
            [
                71.58,
                1708059600
            ],
            [
                72.04,
                1708405200
            ],
            [
                73.2,
                1708491600
            ],
            [
                72.78,
                1708578000
            ],
            [
                73.55,
                1708664400
            ],
            [
                72.95,
                1708923600
            ],
            [
                73.02,
                1709010000
            ],
            [
                72.7,
                1709096400
            ],
            [
                72.1,
                1709182800
            ],
            [
                72.31,
                1709269200
            ],
            [
                72.25,
                1709528400
            ],
            [
                72.99,
                1709614800
            ],
            [
                72.63,
                1709701200
            ],
            [
                73.66,
                1709787600
            ],
            [
                75.12,
                1709874000
            ],
            [
                75.32,
                1710129600
            ],
            [
                75.08,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4098,
        "drug_name": "TAVNEOS (avacopan)",
        "clinical_trial_id": "NCT02994927",
        "has_trial_insight_page": 0,
        "indication": "Associated vasculitis (AAV)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-10-08",
        "link": "https:\/\/ir.chemocentryx.com\/news-releases\/news-release-details\/chemocentryx-announces-fda-approval-tavneostm-avacopan-anca",
        "note": "FDA approval announced October 8, 2021.",
        "company_entity_id": 372,
        "company_ticker": "AMGN",
        "company_name": "Amgen Inc.",
        "company_price": "276.5400",
        "company_change": 1.18,
        "company_percent_change": 0.43,
        "company_optionable": 1,
        "company_number_of_shares": 535918901,
        "price_change_sparkline": [
            [
                311.832823699025,
                1706677200
            ],
            [
                322.053272003295,
                1706763600
            ],
            [
                320.693853151174,
                1706850000
            ],
            [
                319.483275779212,
                1707109200
            ],
            [
                313.62884422628,
                1707195600
            ],
            [
                293.584858231498,
                1707282000
            ],
            [
                292.572736166415,
                1707368400
            ],
            [
                288.871544693121,
                1707454800
            ],
            [
                292.155980021969,
                1707714000
            ],
            [
                288.236487711108,
                1707800400
            ],
            [
                287.829654332006,
                1707886800
            ],
            [
                289.07,
                1707973200
            ],
            [
                283.7,
                1708059600
            ],
            [
                283.51,
                1708405200
            ],
            [
                283.46,
                1708491600
            ],
            [
                285.18,
                1708578000
            ],
            [
                289.18,
                1708664400
            ],
            [
                286.37,
                1708923600
            ],
            [
                278.49,
                1709010000
            ],
            [
                277.46,
                1709096400
            ],
            [
                273.83,
                1709182800
            ],
            [
                280.33,
                1709269200
            ],
            [
                279.39,
                1709528400
            ],
            [
                276.65,
                1709614800
            ],
            [
                276.59,
                1709701200
            ],
            [
                272.86,
                1709787600
            ],
            [
                273.75,
                1709874000
            ],
            [
                275.36,
                1710129600
            ],
            [
                276.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3269,
        "drug_name": "DEXTENZA",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Allergic conjunctivitis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-10-11",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20211011005575\/en\/",
        "note": "sNDA approved October 11, 2021.",
        "company_entity_id": 222,
        "company_ticker": "OCUL",
        "company_name": "Ocular Therapeutix Inc.",
        "company_price": "9.2900",
        "company_change": -0.43999999999999995,
        "company_percent_change": -4.52,
        "company_optionable": 1,
        "company_number_of_shares": 79418626,
        "price_change_sparkline": [
            [
                4.86,
                1706677200
            ],
            [
                5.25,
                1706763600
            ],
            [
                5.18,
                1706850000
            ],
            [
                4.95,
                1707109200
            ],
            [
                5.04,
                1707195600
            ],
            [
                5,
                1707282000
            ],
            [
                5.03,
                1707368400
            ],
            [
                5.68,
                1707454800
            ],
            [
                5.88,
                1707714000
            ],
            [
                5.62,
                1707800400
            ],
            [
                6.46,
                1707886800
            ],
            [
                6.86,
                1707973200
            ],
            [
                7.58,
                1708059600
            ],
            [
                7.52,
                1708405200
            ],
            [
                7.52,
                1708491600
            ],
            [
                9.7,
                1708578000
            ],
            [
                9.86,
                1708664400
            ],
            [
                9.9,
                1708923600
            ],
            [
                9.9,
                1709010000
            ],
            [
                9.95,
                1709096400
            ],
            [
                10.06,
                1709182800
            ],
            [
                10.75,
                1709269200
            ],
            [
                10.88,
                1709528400
            ],
            [
                10.93,
                1709614800
            ],
            [
                10.83,
                1709701200
            ],
            [
                10.37,
                1709787600
            ],
            [
                9.98,
                1709874000
            ],
            [
                9.73,
                1710129600
            ],
            [
                9.29,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6733,
        "drug_name": "VERZENIO (Abemaciclib)",
        "clinical_trial_id": "NCT03155997",
        "has_trial_insight_page": 0,
        "indication": "HR+ \/ HER2- breast cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-10-13",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-approves-verzenio-abemaciclib-as-the-first-and-only-cdk46-inhibitor-for-certain-people-with-hr-her2--high-risk-early-breast-cancer-301398910.html",
        "note": "Approved October 13, 2021. ",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7922,
        "drug_name": "KEYTRUDA (pembrolizumab) + chemo with or without bevacizumab",
        "clinical_trial_id": "NCT03635567",
        "has_trial_insight_page": 0,
        "indication": "Cervical Cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-10-13",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20211013006053\/en\/FDA-Approves-Merck%E2%80%99s-KEYTRUDA%C2%AE-pembrolizumab-Plus-Chemotherapy-With-or-Without-Bevacizumab-as-Treatment-for-Patients-With-Persistent-Recurrent-or-Metastatic-Cervical-Cancer-Whose-Tumors-Express-PD-L1-CPS-%E2%89%A51",
        "note": "Approved October 13, 2021. ",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7856,
        "drug_name": "TECENTRIQ (atezolizumab)",
        "clinical_trial_id": "NCT02486718",
        "has_trial_insight_page": 0,
        "indication": "Non-Small Cell Lung Cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-10-15",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20211015005506\/en\/",
        "note": "Approved October 15, 2021. ",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6249,
        "drug_name": "TYRVAYA (varenicline solution)",
        "clinical_trial_id": "NCT04036292",
        "has_trial_insight_page": 0,
        "indication": "Dry eye disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-10-18",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/oyster-point-pharma-announces-fda-approval-of-tyrvaya-varenicline-solution-nasal-spray-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease-301402070.html",
        "note": "Approved October 18, 2021.",
        "company_entity_id": 851,
        "company_ticker": "VTRS",
        "company_name": "Viatris Inc.",
        "company_price": "12.0600",
        "company_change": 0.09,
        "company_percent_change": 0.75,
        "company_optionable": 1,
        "company_number_of_shares": 1187569149,
        "price_change_sparkline": [
            [
                11.6559127625202,
                1706677200
            ],
            [
                11.754943457189,
                1706763600
            ],
            [
                11.7351373182553,
                1706850000
            ],
            [
                11.4677544426494,
                1707109200
            ],
            [
                11.7747495961228,
                1707195600
            ],
            [
                11.6262035541195,
                1707282000
            ],
            [
                11.4479483037157,
                1707368400
            ],
            [
                11.5667851373183,
                1707454800
            ],
            [
                11.8341680129241,
                1707714000
            ],
            [
                11.8539741518578,
                1707800400
            ],
            [
                11.9530048465267,
                1707886800
            ],
            [
                12.6957350565428,
                1707973200
            ],
            [
                12.933408723748,
                1708059600
            ],
            [
                13.1116639741519,
                1708405200
            ],
            [
                13.1314701130856,
                1708491600
            ],
            [
                13.2305008077544,
                1708578000
            ],
            [
                13.3988529886914,
                1708664400
            ],
            [
                13.2998222940226,
                1708923600
            ],
            [
                13.101760904685,
                1709010000
            ],
            [
                12.1708723747981,
                1709096400
            ],
            [
                12.2500969305331,
                1709182800
            ],
            [
                12.4679644588045,
                1709269200
            ],
            [
                12.2401938610662,
                1709528400
            ],
            [
                12.1609693053312,
                1709614800
            ],
            [
                12.0817447495961,
                1709701200
            ],
            [
                12.2104846526656,
                1709787600
            ],
            [
                12.26,
                1709874000
            ],
            [
                11.97,
                1710129600
            ],
            [
                12.06,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6249,
        "drug_name": "TYRVAYA (varenicline solution)",
        "clinical_trial_id": "NCT04036292",
        "has_trial_insight_page": 0,
        "indication": "Dry eye disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-10-18",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/oyster-point-pharma-announces-fda-approval-of-tyrvaya-varenicline-solution-nasal-spray-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease-301402070.html",
        "note": "Approved October 18, 2021.",
        "company_entity_id": 718,
        "company_ticker": "OYST",
        "company_name": "Oyster Point Pharma Inc.",
        "company_price": "11.1700",
        "company_change": 0,
        "company_percent_change": 0,
        "company_optionable": 0,
        "company_number_of_shares": 26844292,
        "statuses": []
    },
    {
        "id": 5071,
        "drug_name": "ZIMHI (naloxone HCI Injection)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Opioid overdose",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-10-18",
        "link": "https:\/\/www.globenewswire.com\/news-release\/2021\/10\/18\/2315581\/32832\/en\/Adamis-Receives-FDA-Approval-for-ZIMHI.html",
        "note": "Approved October 18, 2021. ",
        "company_entity_id": 15,
        "company_ticker": "ADMP",
        "company_name": "DMK Pharmaceuticals Corp Com Par $0.001",
        "company_price": "0.7751",
        "company_change": 0.01,
        "company_percent_change": 0.85,
        "company_optionable": 0,
        "company_number_of_shares": 9359133,
        "statuses": []
    }
]